Northeast Wisconsin Retina Associates

Meet Dr. Charles Hejny, a Wisconsin native who specializes in retinal care for patients at our Green Bay and Sheboygan locations. Outside of his medical practice, he dedicates his time to exercising and enjoying quality moments with his wife and children. Learn more: https://brnw.ch/21x3obr

Patient feedback helps highlight the importance of creating a welcoming and professional care experience. We are committed to helping patients feel informed, supported, and confident in their eye care decisions.

In our blog, we break down what retinal detachment is and the critical warning signs you should never ignore. Learn more about how recognizing these symptoms early can help you protect your sight and get the timely care you need: https://brnw.ch/21x3cGn

Diabetic retinopathy often develops quietly without any early symptoms, making regular eye exams essential for protecting your sight. Learn more about the symptoms and treatment options to help you stay proactive in managing your health and preventing vision loss: https://brnw.ch/21x35yu

Adaptive sports can play an important role in supporting confidence, physical activity, and community for individuals with visual impairment. Learn more about how Beep Baseball has helped create opportunities for blind and visually impaired athletes through teamwork and competition: https://brnw.ch/21x31Ki

Beep Baseball for the blind and visually impaired: Where’s the Beep? | Ophthalmology Times - Clinical Insights for Eye Specialists 2026 marks 50 years of play.

Our practice is dedicated to treating retinal disorders, offering care from seven specialists across six convenient locations. With decades of combined experience serving Northeastern Wisconsin and Upper Michigan, we remain committed to helping patients protect their vision. Learn more: https://brnw.ch/21x2PHR

Testimonials like these remind us why we do what we do. We’re grateful to provide care and support to our patients every step of the way.

Ocugen’s investigational gene therapy, OCU410, showed promising results in reducing geographic atrophy progression in patients with dry age-related macular degeneration. The therapy demonstrated safety and structural benefits, supporting plans for a Phase 3 trial later in 2026. Learn more: https://brnw.ch/21x2CI5

Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months | Ophthalmology Times - Clinical Insights for Eye Specialists Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

The first quarter of 2026 saw important advancements in ophthalmology, including treatments for presbyopia, age-related macular degeneration, dry eye disease, glaucoma, corneal dystrophy, and geographic atrophy. New technologies are helping improve patient care. Learn more: https://brnw.ch/21x2ufC

Q1 2026 happenings in ophthalmology: Major highlights | Ophthalmology Times - Clinical Insights for Eye Specialists Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

Our North Fond du Lac Retina Center provides care for patients across Northeastern Wisconsin and Upper Michigan. We offer comprehensive diagnosis and treatment for a wide range of retinal conditions. Learn more: https://brnw.ch/21x2pYa